End-of-day quote
Korea S.E.
03:30:00 28/06/2024 am IST
5-day change
1st Jan Change
1,51,500
KRW
-4.54%
+10.66%
-37.14%
Medy-Tox Inc.'s Equity Buyback announced on June 7, 2022, has closed with 39,777 shares, representing 0.66% for KRW 4,574.17 million.
The company closed its plan on July 6, 2022.
Medy-Tox Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
16/05
CI
Medy-Tox Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
21/03
CI
South Korean Shares Close Marginally Lower on North Korea's Artillery Shells Firing
05/01
MT
Medy Tox Establishes Subsidiary Luvantas in California
05/01
MT
Medytox, Inc. Announces the Formation of Luvantas Subsidiary
03/01
CI
Medytox, Inc. Announces Executive Appointments in Luvantas, Inc
03/01
CI
Medy-Tox Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
13/11
CI
Medy-Tox Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
11/23/11
CI
AEON Biopharma, Inc. completed the acquisition of Priveterra Acquisition Corp. from Priveterra Sponsor, LLC, Empyrean Capital Overseas Master Fund, Ltd., managed by Empyrean Capital Partners, LP, Medy-Tox Inc., Daewoong pharmaceutical Co.,Ltd, Strathspey Crown LLC and others in a reverse merger transaction.
21/23/21
CI
Medy-Tox Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
15/23/15
CI
Medy-Tox Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
21/23/21
CI
AEON Biopharma, Inc. entered into a definitive business combination agreement to acquire Priveterra Acquisition Corp. from Priveterra Sponsor, LLC, Empyrean Capital Overseas Master Fund, Ltd., managed by Empyrean Capital Partners, LP, Medy-Tox Inc., Daewoong pharmaceutical Co.,Ltd, Strathspey Crown LLC and others in a reverse merger transaction.
13/22/13
CI
Medy-Tox Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
14/22/14
CI
Tranche Update on Medy-Tox Inc.'s Equity Buyback Plan announced on August 17, 2022.
27/22/27
CI
Medy-Tox Inc.'s Equity Buyback announced on August 17, 2022, has closed with 41,771 shares, representing 0.70% for KRW 5,084.38 million.
22/22/22
CI
Medy-Tox Inc.(KOSDAQ:A086900) dropped from FTSE All-World Index
19/22/19
CI
Medy-Tox Inc. announces an Equity Buyback for 41,771 shares.
17/22/17
CI
Medy-Tox Inc. authorizes a Buyback Plan.
17/22/17
CI
Medy-Tox Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
12/22/12
CI
Tranche Update on Medy-Tox Inc.'s Equity Buyback Plan announced on June 7, 2022.
08/22/08
CI
Medy-Tox Inc.'s Equity Buyback announced on June 7, 2022, has closed with 39,777 shares, representing 0.66% for KRW 4,574.17 million.
06/22/06
CI
Medy-Tox Inc. announces an Equity Buyback for 39,777 shares.
07/22/07
CI
Medy-Tox Inc. authorizes a Buyback Plan.
07/22/07
CI
Medy-Tox Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
16/22/16
CI
Tranche Update on Medy-Tox Inc.'s Equity Buyback Plan announced on February 18, 2022.
05/22/05
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Medy Tox Inc is a Korea-based company engaged in the development, manufacture and marketing of biopharmaceuticals. The Companyâs main product is type A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy. Its products are also used in chin plastic surgeries. The Company provides its products under the brand names of Medytoxin, Neurox, Siax, and Neuramis. In addition, the Company develops and sells medical devices such as injectors under the brand names of Neurajet, Neurafen and others. The Company also engages in technology transfer. The Company distributes its products in domestic and overseas markets such as Japan, China, Russia and Europe.
More about the company
Last Close Price
1,51,500
KRW
Average target price
2,68,000
KRW
Spread / Average Target
+76.90%
Consensus
1st Jan change
Capi.
-37.14% 740M +2.99% 95.18B -4.34% 37.55B -10.41% 33.75B +75.79% 28.2B -14.61% 15.63B -3.46% 13.63B -12.31% 11.5B +184.77% 10.81B -54.13% 9.23B
Biopharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1